The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Renowned Hindi and Marathi actress Pravina Deshpande passed away at 60 after battling multiple myeloma since 2019. Known for Ghar Ek Mandir, Kumkum, and films like Ready, she faced skin eruptions, ...

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...